Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05875168 · ClinicalTrials.gov registry record · Phase 1

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
540
Enrollment target
20
Study locations

NCT05875168 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 540 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05875168, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
540 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG DS-3939a

Study Locations (20)

Other

  • UZ Leuven - Leuven
  • McGill University Health Center - Montreal
  • Princess Margaret Cancer Center - Toronto
  • Beijing Cancer Hospital - Beijing
  • Shandong Cancer Hospital - Jinan
  • The Second Peoples Hospital of Neijiang - Neijiang
  • Shanghai East Hospital - Shanghai
  • Centre Léon Bérard - Lyon
  • Assistance Publique- de Marseille - Marseille
  • Chu Strasbourg - Strasbourg
  • Institut Claudius Regaud - Toulouse
  • Institut Gustave Roussy - Villejuif
  • National Cancer Center Hospital - Chūōku
  • Kansai Medical University Hospital - Hirakata-shi

Florida

  • Florida Cancer Specialists - Sarasota

Oregon

  • Oregon Health & Science University - Portland

Rhode Island

  • Rhode Island Hospital - Providence

Texas

  • University of Texas M.D. Anderson Cancer Center - Houston

Utah

  • Huntsman Cancer Institute, University of Utah - Salt Lake City

Wisconsin

  • The Medical College of Wisconsin, INC - Milwaukee

Trial Details

FieldValue
Enrollment Target 540 participants
Start Date 2023-08-18
Est. Completion 2027-02-15
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05875168

The ClinicalTrials.gov registry entry for NCT05875168 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (184% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which DS-3939a is the first listed.

NCT05875168 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT05875168 about?

NCT05875168 is a clinical study titled "First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors". This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

What is the current status of trial NCT05875168?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 540 participants. The study started on 2023-08-18. Estimated completion is 2027-02-15.

What conditions does trial NCT05875168 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT05875168?

The interventions under investigation include: DS-3939a (DRUG).

Who is sponsoring clinical trial NCT05875168?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05875168 being conducted?

This trial has 20 study locations across Florida, Oregon, Rhode Island, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.